Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
InnoPCV + PD-1 in Advanced Solid Tumors
NCT06497010Phase 1Recruiting
- Sponsor
- Affiliated Hospital of Guizhou Medical University
- Start
- Aug 2024
- Primary completion
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of InnoPCV in solid tumor (advanced stage), sponsored by Affiliated Hospital of Guizhou Medical University. Primary endpoint: Recommended Phase 2 Dose at 90 days. Started Aug 2024; status: recruiting.
02
Drugs
InnoPCV
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06497010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06497010.